Clinical Trials
Numerous clinical trials evaluate nab-paclitaxel across Early Phase 1 through Phase 4, targeting conditions such as metastatic pancreatic cancer, HER2-negative breast cancer, esophageal squamous cell carcinoma, and chemotherapy-induced peripheral neuropathy. Sponsored by academic institutes, hospital networks, and biotechnology organizations like M.D. Anderson Cancer Center and Fudan University, these studies span recruitment statuses including active, not yet recruiting, completed, withdrawn, and terminated. Ongoing clinical research continues to assess novel combination therapies and neoadjuvant regimens in refractory oncology indications.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06096844 | RECRUITING | Advanced Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8 |
National Cancer Institute (NCI) |
2024-07-19 | PHASE3 |
| NCT07060807 | RECRUITING | Breast Neoplasms |
Merck Sharp & Dohme LLC |
2025-07-21 | PHASE3 |
| NCT04198766 | RECRUITING | Solid Tumor; Non-Small Cell Lung Cancer; Head and Neck Cancer; Melanoma; Gastric Cancer; Renal Cell Carcinoma; Urothelial Carcinoma; Resectable Non-Small-Cell Lung Cancer |
Inhibrx Biosciences, Inc |
2019-12-10 | PHASE1; PHASE2 |
| NCT06714604 | RECRUITING | Locally Advanced Pancreatic Adenocarcinoma; Borderline Resectable Pancreatic Carcinoma; Pancreas Cancer; Neoadjuvant Chemotherapy; Surgery; Pancreatectomy |
Sahlgrenska University Hospital |
2023-10-18 | PHASE3 |
| NCT07629817 | RECRUITING | Esophageal Squamous Cell Carcinoma |
Henan Cancer Hospital |
2026-06-16 | PHASE3 |
| NCT06731907 | RECRUITING | Non-small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2025-03-30 | PHASE2 |
| NCT06837948 | NOT_YET_RECRUITING | Locally Advanced Non-Small Cell Lung Cancer |
Shanghai Pulmonary Hospital, Shanghai, China |
2025-02-18 | PHASE2 |
| NCT07063745 | RECRUITING | Metastatic Non-small Cell Lung Cancer With MTAP Deletion |
Bristol-Myers Squibb |
2026-01-02 | PHASE2; PHASE3 |
| NCT05919537 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer; Pancreatic Cancer; Locally Advanced Solid Tumor; Metastatic Solid Tumor |
Hummingbird Bioscience |
2023-09-06 | PHASE1 |
| NCT07371611 | RECRUITING | Locally Advanced Oral Squamous Cell Carcinoma; Oral Squamous Cell Carcinoma (OSCC) |
Qunxing Li,MD |
2026-01-01 | PHASE3 |
| NCT06608927 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Arcus Biosciences, Inc. |
2024-12-13 | PHASE3 |
| NCT06109402 | NOT_YET_RECRUITING | Stage II-IIIB(N2) Non-small Cell Lung Cancer |
Shanghai Pulmonary Hospital, Shanghai, China |
2023-12-20 | PHASE2 |
| NCT06958328 | RECRUITING | Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
NRG Oncology |
2025-08-21 | PHASE3 |
| NCT03424005 | RECRUITING | Metastatic Breast Cancer |
Hoffmann-La Roche |
2018-03-30 | PHASE1; PHASE2 |
| NCT07155629 | NOT_YET_RECRUITING | Pancreatic Cancer Resectable |
Helsinki University Central Hospital |
2025-09-01 | PHASE3 |
| NCT06692738 | RECRUITING | Non-small Cell Lung Cancer |
AstraZeneca |
2024-11-18 | PHASE3 |
| NCT07383922 | NOT_YET_RECRUITING | Pancreatic Cancer |
FutureGen Biopharmaceutical (Beijing) Co., Ltd |
2026-02-28 | PHASE3 |
| NCT05257993 | RECRUITING | Pancreatic Ductal Adenocarcinoma |
Onconic Therapeutics Inc. |
2022-03-30 | PHASE1; PHASE2 |
| NCT06439693 | RECRUITING | Breast Cancer Female; Breast Cancer; Breast Cancer Metastatic; Estrogen Receptor-positive Breast Cancer; HER2-positive Breast Cancer; Stage IV Breast Cancer |
Dana-Farber Cancer Institute |
2024-08-08 | PHASE2 |
| NCT07748611 | NOT_YET_RECRUITING | Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma |
Northwestern University |
2027-02-03 | PHASE2 |
| NCT06607185 | ACTIVE_NOT_RECRUITING | Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer; Advanced Solid Tumor; Metastatic Solid Tumor |
Eli Lilly and Company |
2024-10-21 | PHASE1 |
| NCT06998940 | RECRUITING | Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
SWOG Cancer Research Network |
2026-05-13 | PHASE3 |
| NCT07756645 | NOT_YET_RECRUITING | Non-Small Cell Lung Cancer |
AbbVie |
2026-09-22 | PHASE3 |
| NCT05633667 | ACTIVE_NOT_RECRUITING | Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer; Resectable Non-Small-Cell Lung Cancer |
Gilead Sciences |
2023-03-16 | PHASE2 |
| NCT07563738 | RECRUITING | Mesothelioma; Pancreatic Cancer; NSCLC (Advanced Non-small Cell Lung Cancer) |
Orion Corporation, Orion Pharma |
2026-03-27 | PHASE1; PHASE2 |
| NCT07738341 | NOT_YET_RECRUITING | Breast Cancer (Locally Advanced or Metastatic) |
Eddingpharm (Zhuhai) Co., Ltd. |
2026-08-01 | PHASE1; PHASE2 |
| NCT06214572 | RECRUITING | Gall Bladder Cancer |
Tata Memorial Centre |
2024-03-07 | PHASE2; PHASE3 |
| NCT07683221 | NOT_YET_RECRUITING | Pancreatic Cancer |
Shandong Cancer Hospital and Institute |
2026-07-15 | PHASE2 |
| NCT04858009 | RECRUITING | Metastatic Pancreatic Carcinoma; Stage IV Pancreatic Cancer AJCC v8; Metastatic Malignant Neoplasm in the Peritoneum |
Mayo Clinic |
2024-02-15 | PHASE2 |
| NCT07076121 | ACTIVE_NOT_RECRUITING | Pancreatic Ductal Adenocarcinoma |
Bristol-Myers Squibb |
2025-10-23 | PHASE2; PHASE3 |
| NCT06323369 | RECRUITING | Head and Neck Squamous Cell Carcinoma |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2024-03-25 | PHASE2 |
| NCT06586515 | RECRUITING | Pancreatic Ductal Adenocarcinoma; Non-small Cell Lung Cancer; Colorectal Cancer |
Eli Lilly and Company |
2024-09-12 | PHASE1 |
| NCT07463313 | NOT_YET_RECRUITING | Thymoma and Thymic Carcinoma |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2026-03 | PHASE2; PHASE3 |
| NCT07578337 | NOT_YET_RECRUITING | Untreated; Advanced Pancreatic Cancer |
Nelum Corp |
2026-07-15 | PHASE2 |
| NCT06996782 | RECRUITING | Advanced or Metastatic Non-small Cell Lung Cancer |
AstraZeneca |
2025-11-24 | PHASE1; PHASE2 |
| NCT06675136 | RECRUITING | Clinical Stage IVB Gastric Cancer AJCC v8; Metastatic Gastric Adenocarcinoma; Metastatic Malignant Neoplasm in the Peritoneum |
City of Hope Medical Center |
2025-10-29 | PHASE1 |
| NCT07622797 | RECRUITING | Late-stage Resectable Esophageal Squamous Carcinoma |
The First Affiliated Hospital of Henan University of Science and Technology |
2025-11-21 | PHASE2 |
| NCT07277452 | NOT_YET_RECRUITING | Pancreatic Cancer, Adult |
The First Affiliated Hospital with Nanjing Medical University |
2025-12-10 | PHASE2 |
| NCT06894459 | NOT_YET_RECRUITING | Head and Neck Cancers |
Beijing Tongren Hospital |
2025-05-08 | PHASE2 |
| NCT07226856 | RECRUITING | Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 |
Mayo Clinic |
2025-12-12 | PHASE2 |
| NCT07475234 | NOT_YET_RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Xiuchao Wang |
2026-03 | PHASE1; PHASE2 |
| NCT07020221 | RECRUITING | Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer; Colorectal Cancer; Solid Tumor, Adult; G12D Mutated KRAS |
Verastem, Inc. |
2025-06-24 | PHASE1; PHASE2 |
| NCT07769502 | NOT_YET_RECRUITING | Pancreatobiliary Cancers; Pancreatic Ductal Adenocarcinoma |
AbbVie |
2026-09-22 | PHASE2 |
| NCT07223047 | RECRUITING | Advanced Solid Malignancies; Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC) |
Bristol-Myers Squibb |
2025-11-25 | PHASE1; PHASE2 |
| NCT05582265 | RECRUITING | Head and Neck Squamous Cell Carcinomas |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2022-10-28 | PHASE3 |
| NCT07238283 | RECRUITING | First-line Treatment of Metastatic Pancreatic Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2025-12-02 | PHASE3 |
| NCT06904378 | RECRUITING | Metastatic Pancreatic Ductal Adenocarcinoma |
Washington University School of Medicine |
2026-03-25 | PHASE1; PHASE2 |
| NCT06722911 | RECRUITING | Pancreatic Cancer Resectable |
Zhejiang Provincial People's Hospital |
2024-11-15 | PHASE2 |
| NCT07436741 | RECRUITING | Pancreatic Cancer, Adult |
Tianjin Medical University Cancer Institute and Hospital |
2026-03-03 | PHASE3 |
| NCT07049055 | RECRUITING | Pancreatic Cancer, Metastatic; PDAC - Pancreatic Ductal Adenocarcinoma |
Engeneic Pty Limited |
2026-01-12 | PHASE1; PHASE2 |
| NCT07457346 | RECRUITING | Head and Neck Cancer Squamous Cell Carcinoma |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-01-01 | PHASE2 |
| NCT04241276 | ACTIVE_NOT_RECRUITING | Pancreatic Cancer |
Queen Mary University of London |
2020-04-30 | PHASE2 |
| NCT07562152 | RECRUITING | Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Adenocarcinoma Metastatic; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma |
Immuneering Corporation |
2026-06-05 | PHASE3 |
| NCT05502237 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer |
Gilead Sciences |
2022-10-12 | PHASE3 |
| NCT05786924 | RECRUITING | Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D |
Institut de Recherches Internationales Servier |
2023-04-18 | PHASE1; PHASE2 |
| NCT07493993 | NOT_YET_RECRUITING | ESCC |
Tianjin Medical University Cancer Institute and Hospital |
2026-06-01 | PHASE2 |
| NCT06361888 | RECRUITING | Metastatic Pancreatic Cancer |
Hutchmed |
2024-05-08 | PHASE2; PHASE3 |
| NCT07601737 | RECRUITING | Head and Neck Squamous Cell Carcinoma; Head and Neck Squamous Cell Carcinoma (HNSCC); Head & Neck Cancer; Neoadjuvant Therapy |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2026-04-20 | PHASE2 |
| NCT06938503 | NOT_YET_RECRUITING | Pancreatic Cancer, Adult |
Tianjin Medical University Cancer Institute and Hospital |
2025-04-21 | PHASE2 |
| NCT06926868 | RECRUITING | Breast Neoplasms |
Bristol-Myers Squibb |
2025-09-11 | PHASE2; PHASE3 |
| NCT07111832 | RECRUITING | PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
2025-08-20 | PHASE3 |
| NCT04901741 | NOT_YET_RECRUITING | Metastatic Pancreatic Cancer |
TME Pharma AG |
2026-01 | PHASE2 |
| NCT06393400 | RECRUITING | Unresectable or Metastatic Advanced Pancreatic Ductal Adenocarcinoma |
John Lenehan |
2025-01-08 | PHASE1 |
| NCT06132958 | ACTIVE_NOT_RECRUITING | Endometrial Cancer |
Merck Sharp & Dohme LLC |
2023-12-06 | PHASE3 |
| NCT07595770 | RECRUITING | Esophageal Squamous Cell Carcinoma (ESCC) |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2026-05-22 | PHASE2 |
| NCT04570943 | RECRUITING | Locally Advanced Pancreatic Adenocarcinoma |
Institut du Cancer de Montpellier - Val d'Aurelle |
2021-06-16 | PHASE2 |
| NCT07433673 | RECRUITING | Colon and Rectal Cancer |
Columbia University |
2026-08 | PHASE2 |
| NCT07733830 | RECRUITING | Esophageal Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2026-07-31 | PHASE2 |
| NCT04683315 | RECRUITING | Pancreatic Cancer |
Medical College of Wisconsin |
2021-04-01 | PHASE2 |
| NCT07258147 | NOT_YET_RECRUITING | Lung Cancer (SCLC) |
Sichuan University |
2026-10-31 | PHASE2 |
| NCT06964906 | RECRUITING | ER+/HER2- Breast Cancer |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2025-03-04 | PHASE2 |
| NCT07092449 | NOT_YET_RECRUITING | Gastroesophageal Junction; Gastric / Gastroesophageal Junction Adenocarcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy |
Tang-Du Hospital |
2025-08-01 | |
| NCT06569225 | NOT_YET_RECRUITING | Cholangiocarcinoma Resectable |
University Health Network, Toronto |
2024-12-15 | PHASE2 |
| NCT07705919 | NOT_YET_RECRUITING | Borderline Resectable Pancreatic Ductal Adenocarcinoma |
Ohio State University Comprehensive Cancer Center |
2026-09-01 | PHASE1; PHASE2 |
| NCT07272109 | NOT_YET_RECRUITING | Pancreatic Cancer |
Fudan University |
2026-01-01 | PHASE3 |
| NCT07253662 | RECRUITING | Adenocarcinoma Pancreas |
Northwell Health |
2026-01-11 | PHASE1 |
| NCT07018063 | NOT_YET_RECRUITING | Gastric (Cardia, Body) Cancer; Stomach Adenocarcinoma; Locally Advanced |
zhoujing |
2025-10-01 | PHASE2 |
| NCT05791097 | WITHDRAWN | Non-small Cell Lung Cancer (NSCLC) |
Novartis Pharmaceuticals |
2023-07-28 | PHASE3 |
| NCT07307443 | NOT_YET_RECRUITING | SMARCA4-Deficient Tumor; Locally Advanced or Metastatic Lung Cancer |
Zhijie Wang |
2026-02-01 | PHASE2 |
| NCT07255404 | RECRUITING | Pancreatic Ductal Adenocarcinoma (PDAC) |
BioNTech SE |
2025-12-04 | PHASE2 |
| NCT05562297 | NOT_YET_RECRUITING | Pancreatic Cancer, Stage IB; Pancreatic Cancer, Stage IIA; Pancreatic Cancer, Stage IIB; Pancreatic Cancer Stage III |
Shanghai Zhongshan Hospital |
2025-03-20 | PHASE2 |
| NCT06561685 | RECRUITING | Metastatic Solid Tumor; Advanced Solid Tumor; Non-small Cell Lung Cancer; SMARCA4-Deficient Tumor |
Eli Lilly and Company |
2024-09-19 | PHASE1 |
| NCT07296341 | RECRUITING | Locally Advanced or Metastatic Pancreatic Cancer With |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
2026-01-08 | PHASE1; PHASE2 |
| NCT07438106 | RECRUITING | Locally Advanced Pancreatic Cancer With KRAS G12D Mutation |
The First Affiliated Hospital with Nanjing Medical University |
2026-01-28 | PHASE2 |
| NCT07317609 | RECRUITING | Esophageal Squamous Cell Carcinoma (ESCC) |
Shanghai Zhongshan Hospital |
2025-07-15 | PHASE1 |
| NCT06532331 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Cancer |
Ono Pharmaceutical Co., Ltd. |
2023-12-06 | PHASE1 |
| NCT06662669 | NOT_YET_RECRUITING | Metastatic Pancreatic Cancer |
Shanghai YingLi Pharmaceutical Co. Ltd. |
2024-11-30 | PHASE1; PHASE2 |
| NCT07145931 | NOT_YET_RECRUITING | Head and Neck Cancer Squamous Cell Carcinoma; Skull Base--Cancer; Neoadjuvant Chemoimmunotherapy; Objective Response Rate |
Sun Yat-sen University |
2025-09-20 | PHASE2 |
| NCT04253964 | RECRUITING | Nonsmall Cell Lung Cancer; Performance Status |
Wake Forest University Health Sciences |
2020-07-01 | PHASE2 |
| NCT07259317 | RECRUITING | Adenocarcinoma; Carcinoma, Pancreatic Ductal |
Corcept Therapeutics |
2026-01-27 | PHASE2 |
| NCT07089199 | RECRUITING | NSCLC; Tislelizumab; Anlotinib; Nab-paclitaxel |
Qilu Hospital of Shandong University |
2025-07-25 | PHASE2 |
| NCT06483555 | RECRUITING | Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer; Basal Cell Neoplasm |
UNC Lineberger Comprehensive Cancer Center |
2025-02-06 | PHASE1; PHASE2 |
| NCT03181100 | ACTIVE_NOT_RECRUITING | Metastatic Thyroid Gland Carcinoma; Poorly Differentiated Thyroid Gland Carcinoma; Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8; Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8; Thyroid Gland Anaplastic Carcinoma; Unresectable Thyroid Gland Carcinoma |
M.D. Anderson Cancer Center |
2017-07-27 | PHASE2 |
| NCT07280377 | ACTIVE_NOT_RECRUITING | Anal Cancer Metastatic; Squamous Cell Carcinoma of the Anus Stage Unspecified; Pancreatic Cancer Metastatic; Unresectable Pancreatic Carcinoma |
Oncolytics Biotech |
2021-10-27 | PHASE1; PHASE2 |
| NCT06103864 | RECRUITING | Breast Cancer |
AstraZeneca |
2023-11-23 | PHASE3 |
| NCT06312176 | RECRUITING | Breast Neoplasms |
Merck Sharp & Dohme LLC |
2024-04-14 | PHASE3 |
| NCT07071337 | RECRUITING | Metastatic Breast Cancer |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
2025-07-18 | PHASE3 |
| NCT07088731 | NOT_YET_RECRUITING | Cervical Carcinoma |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2025-09 | PHASE2 |
| NCT07163273 | RECRUITING | Pancreatic Ductal Adenocarcinoma |
Northwell Health |
2025-06-20 | PHASE2 |
| NCT05420454 | RECRUITING | Breast Cancer |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2022-07-10 | PHASE4 |
| NCT06975475 | NOT_YET_RECRUITING | Breast Cancer |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2025-06-01 | PHASE2 |
| NCT04999761 | RECRUITING | Advanced or Metastatic Solid Tumor; Pancreatic Ductal Adenocarcinoma; Colorectal Cancer; Non-small Cell Lung Cancer; Gastric Cancer; Alveolar Soft Part Sarcoma; Esophageal Cancer; Head and Neck Cancer; Biliary Tract Cancer |
Taiho Pharmaceutical Co., Ltd. |
2021-06-01 | PHASE1 |
| NCT06421298 | RECRUITING | Lung Cancer |
Jinghui Wang |
2024-05-17 | PHASE2 |
| NCT07618910 | NOT_YET_RECRUITING | Esophageal Squamous Cell Carcinoma |
Tang-Du Hospital |
2026-05-30 | PHASE2 |
| NCT06951997 | RECRUITING | Metastatic Pancreatic Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2025-03-07 | PHASE2 |
| NCT07310069 | ENROLLING_BY_INVITATION | Gallbladder Cancer Unresectable |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2025-05-01 | PHASE2 |
| NCT05685602 | SUSPENDED | Metastatic Pancreatic Ductal Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma |
National Cancer Institute (NCI) |
2023-06-12 | PHASE1 |
| NCT07751055 | RECRUITING | Esophageal Squamous Cell Carcinoma (ESCC) |
Sun Yat-sen University |
2026-08-01 | PHASE2 |
| NCT07549958 | RECRUITING | Pancreatic Cancer; Pancreatic Cancer Metastatic |
University of California, Irvine |
2026-03-24 | PHASE1 |
| NCT04158635 | SUSPENDED | Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Carcinoma |
City of Hope Medical Center |
2021-09-01 | PHASE1 |
| NCT07348107 | NOT_YET_RECRUITING | Advanced Pancreatic Ductal Adenocarcinoma |
Daniel Breadner |
2026-02-15 | PHASE1 |
| NCT06861894 | NOT_YET_RECRUITING | Esophageal Squamous Cell Carcinoma |
Zhigang Li |
2025-07 | PHASE2 |
| NCT07452601 | RECRUITING | Esophageal Squamous Cell Carcinoma |
Tang-Du Hospital |
2026-05-05 | PHASE2 |
| NCT05075993 | ACTIVE_NOT_RECRUITING | Metastatic Esophageal; Gastric Cancer; Metastatic Head and Neck Carcinoma; Metastatic Hepatocellular Carcinoma; Metastatic HPV Related Solid Tumors; Metastatic Ovarian Carcinoma; Metastatic Soft Tissue Sarcoma; Metastatic Uveal Melanoma |
M.D. Anderson Cancer Center |
2021-11-12 | PHASE1 |
| NCT05497778 | ACTIVE_NOT_RECRUITING | Pancreas Cancer |
M.D. Anderson Cancer Center |
2022-10-21 | PHASE1 |
| NCT06770452 | RECRUITING | Metastatic Pancreatic Carcinoma |
Zhejiang University |
2025-03-25 | PHASE2 |
| NCT05355298 | ACTIVE_NOT_RECRUITING | Pancreatic Cancer; PDAC; Pancreatic Ductal Adenocarcinoma |
Amplia Therapeutics Limited |
2022-05-31 | PHASE1; PHASE2 |
| NCT05382286 | ACTIVE_NOT_RECRUITING | Triple Negative Breast Cancer; PD-L1 Positive |
Gilead Sciences |
2022-07-25 | PHASE3 |
| NCT05827055 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Cancer |
Georgetown University |
2024-01-31 | PHASE2 |
| NCT05982522 | WITHDRAWN | Solid Tumor |
InxMed (Shanghai) Co., Ltd. |
2025-08-13 | PHASE1; PHASE2 |
| NCT06808971 | RECRUITING | Gastric Adenocarcinoma; Gastro-esophageal Junction Adenocarcinoma |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2025-02-28 | PHASE2 |
| NCT07454031 | NOT_YET_RECRUITING | Peritoneal (Metastatic) Cancer |
Peking University |
2026-03-15 | PHASE1 |
| NCT06423326 | RECRUITING | Borderline Resectable Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Adenocarcinoma; Stage I Pancreatic Cancer AJCC v8; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8 |
Emory University |
2024-08-06 | PHASE2 |
| NCT04115163 | ACTIVE_NOT_RECRUITING | Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 |
Anne Noonan |
2020-06-24 | PHASE2 |
| NCT05969171 | RECRUITING | Pancreatic Cancer Metastatic |
Fudan University |
2023-12-05 | PHASE2 |
| NCT05227664 | ACTIVE_NOT_RECRUITING | Metastatic Triple-negative Breast Cancer; Locally Advanced Triple-negative Breast Cancer |
Akeso |
2022-03-23 | PHASE2 |
| NCT07233252 | RECRUITING | Renal Pelvic Carcinoma; Tislelizumab; PD-1 Inhibitor; Kidney-sparing; Nab-paclitaxel |
Tianjin Medical University Second Hospital |
2025-11-25 | PHASE2 |
| NCT03606967 | RECRUITING | Anatomic Stage IV Breast Cancer AJCC v8; Invasive Breast Carcinoma; Metastatic Triple-Negative Breast Carcinoma |
National Cancer Institute (NCI) |
2021-04-13 | PHASE2 |
| NCT07245797 | NOT_YET_RECRUITING | Breast Cancer |
Zhimin Shao |
2025-12-15 | PHASE2 |
| NCT05281471 | RECRUITING | Platinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer; High-grade Serous Ovarian Cancer; Endometrioid Ovarian Cancer; Ovarian Clear Cell Carcinoma |
Genelux Corporation |
2022-08-31 | PHASE3 |
| NCT02207465 | ACTIVE_NOT_RECRUITING | Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy; Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy |
Abramson Cancer Center at Penn Medicine |
2014-07 | PHASE1 |
| NCT06914440 | RECRUITING | Breast Cancer |
Xijing Hospital |
2025-06-05 | PHASE2 |
| NCT06538896 | RECRUITING | Triple-negative Breast Cancer; Bone Metastases |
Zhejiang Cancer Hospital |
2024-08-20 | PHASE2 |
| NCT07353723 | RECRUITING | Head & Neck Cancer |
Tang-Du Hospital |
2025-11-15 | PHASE2 |
| NCT06122493 | RECRUITING | Esophageal Squamous Cell Carcinoma |
Ruijin Hospital |
2022-11-01 | PHASE2 |
| NCT05852691 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Hoffmann-La Roche |
2023-07-18 | PHASE2 |
| NCT06591650 | RECRUITING | Gallbladder Cancer Unresectable |
Fudan University |
2024-10-24 | PHASE2 |
| NCT06447662 | ACTIVE_NOT_RECRUITING | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Pfizer |
2024-06-27 | PHASE1 |
| NCT05451043 | RECRUITING | Pancreatic Cancer; Hepatocellular Cancer; Biliary Tract Cancer; Cholangiocarcinoma |
AHS Cancer Control Alberta |
2023-07-05 | PHASE2 |
| NCT02270814 | ACTIVE_NOT_RECRUITING | Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Cancer of the Head and Neck |
Washington University School of Medicine |
2015-02-02 | PHASE2 |
| NCT05116462 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Innovent Biologics (Suzhou) Co. Ltd. |
2024-03-15 | PHASE3 |
| NCT07055399 | RECRUITING | Locally Advanced Cervical Cancer |
Fujian Cancer Hospital |
2025-08-21 | PHASE2 |
| NCT03492671 | RECRUITING | Pancreas Adenocarcinoma; Resectable Pancreatic Cancer |
Loma Linda University |
2019-07-17 | PHASE2 |
| NCT06994507 | RECRUITING | Chemotherapy-induced Peripheral Neuropathy (CIPN) |
Qilu Pharmaceutical Co., Ltd. |
2025-08-01 | PHASE3 |
| NCT05669482 | ACTIVE_NOT_RECRUITING | KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neoplasm of Pancreas |
Verastem, Inc. |
2023-03-22 | PHASE1; PHASE2 |
| NCT05254171 | RECRUITING | Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV |
Panbela Therapeutics, Inc. |
2022-08-08 | PHASE2; PHASE3 |
| NCT05632328 | ACTIVE_NOT_RECRUITING | Advanced Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer |
Bruno Bockorny |
2024-08-08 | PHASE2 |
| NCT06241469 | NOT_YET_RECRUITING | Gastric Cancer; GastroEsophageal Cancer; Adenocarcinoma |
Wu Jun |
2024-02-03 | PHASE2 |
| NCT06853678 | RECRUITING | Extensive Stage Small Cell Lung Cancer (ES-SCLC) |
Tianjin Medical University Cancer Institute and Hospital |
2025-02-28 | |
| NCT06017323 | WITHDRAWN | Metastatic Pancreatic Cancer |
Georgetown University |
2023-10 | PHASE1 |
| NCT06802757 | RECRUITING | Breast Cancer |
Shandong Cancer Hospital and Institute |
2025-05-01 | PHASE2 |
| NCT06454435 | NOT_YET_RECRUITING | Gastric Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2024-06 | PHASE2 |
| NCT06625320 | ACTIVE_NOT_RECRUITING | Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma |
Revolution Medicines, Inc. |
2024-10-16 | PHASE3 |
| NCT05238831 | WITHDRAWN | Advanced Breast Carcinoma; Advanced Malignant Solid Neoplasm; Advanced Ovarian Carcinoma; Advanced Pancreatic Carcinoma; Advanced Prostate Carcinoma; Advanced Sarcoma; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Recurrent Adult Soft Tissue Sarcoma; Recurrent Breast Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Prostate Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
OHSU Knight Cancer Institute |
2023-01-30 | EARLY_PHASE1 |
| NCT06438627 | RECRUITING | Nasopharyngeal Carcinoma |
XIANG YANQUN |
2024-05-30 | PHASE3 |
| NCT04015778 | ACTIVE_NOT_RECRUITING | Non Small Cell Lung Cancer |
Guangdong Association of Clinical Trials |
2019-08-08 | PHASE2 |
| NCT05017012 | COMPLETED | Advanced or Metastatic Solid Tumors |
Merck Sharp & Dohme LLC |
2021-09-21 | PHASE1 |
| NCT06704724 | TERMINATED | Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung |
Pfizer |
2024-12-10 | PHASE1 |
| NCT06398587 | WITHDRAWN | Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma |
OHSU Knight Cancer Institute |
2024-08-01 | PHASE2 |
| NCT06388135 | NOT_YET_RECRUITING | Esophageal Squamous Cell Carcinoma |
Yang Jianjun, PhD |
2024-05-01 | PHASE4 |
| NCT06370754 | NOT_YET_RECRUITING | Pancreatic Cancer |
Fudan University |
2024-04-30 | PHASE1; PHASE2 |
| NCT04481204 | WITHDRAWN | Borderline Resectable Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Ductal Adenocarcinoma; Resectable Pancreatic Ductal Adenocarcinoma |
M.D. Anderson Cancer Center |
2023-04-18 | PHASE2 |
| NCT04895358 | ACTIVE_NOT_RECRUITING | Breast Neoplasms |
Merck Sharp & Dohme LLC |
2021-06-18 | PHASE3 |
| NCT06793553 | RECRUITING | Metastatic Breast Cancer |
Japan Breast Cancer Research Group |
2024-09-13 | PHASE2 |
| NCT05814354 | ACTIVE_NOT_RECRUITING | Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2023-06-30 | PHASE3 |
| NCT05689671 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer Metastatic |
Nikolaj Frost MD |
2023-12-06 | PHASE4 |
| NCT06901622 | ENROLLING_BY_INVITATION | Gallbladder Cancer and Extrahepatic Cholangiocarcinoma |
The First Affiliated Hospital of Zhengzhou University |
2024-11-08 | PHASE2 |
| NCT04872985 | ACTIVE_NOT_RECRUITING | Breast Cancer; Hormone-receptor Positive Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2021-04-20 | PHASE2 |
| NCT05501665 | RECRUITING | Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8; Stage III Lung Cancer |
Vanderbilt-Ingram Cancer Center |
2023-05-09 | PHASE1; PHASE2 |
| NCT05630183 | COMPLETED | Metastatic Pancreatic Ductal Adenocarcinoma |
Agenus Inc. |
2023-03-27 | PHASE2 |
| NCT05241249 | RECRUITING | Pancreas Cancer |
Susan E. Bates |
2022-02-01 | PHASE2 |
| NCT05173246 | RECRUITING | Esophageal Small Cell Carcinoma |
Sun Yat-sen University |
2020-11-17 | PHASE2 |
| NCT05737303 | RECRUITING | Epithelial Ovarian Carcinoma Stage III; Epithelial Ovarian Carcinoma Stage IV; Fallopian Tube Carcinoma Stage III; Fallopian Tube Carcinoma Stage IV; Primary Peritoneal Carcinoma Stage III; Primary Peritoneal Carcinoma Stage IV |
Women's Hospital School Of Medicine Zhejiang University |
2023-11-27 | PHASE3 |
| NCT06816771 | RECRUITING | Rhabdomyosarcoma, Recurrent, Refractory |
Shandong Cancer Hospital and Institute |
2025-02 | PHASE2 |
| NCT04151277 | UNKNOWN | Neoplasms Pancreatic |
Judith Dixon-Hughes |
2017-11-28 | PHASE2 |
| NCT06140576 | NOT_YET_RECRUITING | Breast Neoplasms |
Zhejiang Cancer Hospital |
2023-11-30 | PHASE1; PHASE2 |
| NCT06173986 | RECRUITING | Esophageal Squamous Cell Carcinoma; Unresectable Locally Advanced Esophageal Cancer |
Shanghai Chest Hospital |
2023-01-10 | PHASE1; PHASE2 |
| NCT06076837 | TERMINATED | Pancreatic Cancer Metastatic; Pancreatic Adenocarcinoma Metastatic |
HonorHealth Research Institute |
2025-01-09 | PHASE1 |
| NCT05203913 | RECRUITING | Muscle-Invasive Bladder Carcinoma |
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
2023-05-01 | PHASE2 |
| NCT06165900 | RECRUITING | Stereotactic Radiotherapy; Immunotherapy; Breast Cancer |
Shengjing Hospital |
2023-09-26 | PHASE2 |
| NCT06289062 | RECRUITING | Cervical Cancer; Neoadjuvant Chemoimmunotherapy; Fertility Preservation |
Tongji Hospital |
2024-05-08 | PHASE2 |
| NCT06359275 | RECRUITING | Pancreatic Cancer |
Fudan University |
2024-06-01 | PHASE2 |
| NCT04137653 | RECRUITING | Breast Cancer |
Shengjing Hospital |
2021-07-19 | PHASE3 |
| NCT06017284 | RECRUITING | Pancreatic Cancer Stage IV; Chemotherapy-induced Nausea and Vomiting |
Fudan University |
2023-11-01 | PHASE3 |
| NCT06119217 | COMPLETED | Pancreatic Cancer |
Trishula Therapeutics, Inc. |
2024-03-25 | PHASE2 |
| NCT02705196 | COMPLETED | Pancreatic Cancer |
Lokon Pharma AB |
2016-11 | PHASE1; PHASE2 |
| NCT06405685 | UNKNOWN | Pancreatic Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-04-27 | PHASE2 |
| NCT04649385 | COMPLETED | Advanced Solid Tumor |
BeiGene |
2021-03-04 | PHASE1 |
| NCT03520686 | TERMINATED | Non Small Cell Lung Cancer |
ImmunityBio, Inc. |
2018-05-18 | PHASE3 |
| NCT04390399 | ACTIVE_NOT_RECRUITING | Pancreatic Cancer |
ImmunityBio, Inc. |
2020-07-21 | PHASE2 |
| NCT06009848 | UNKNOWN | Bladder Cancer |
Tianjin Medical University Second Hospital |
2022-10-10 | PHASE2 |
| NCT06786026 | RECRUITING | TNBC, Triple Negative Breast Cancer |
Fudan University |
2024-10-09 | PHASE2 |
| NCT04216472 | TERMINATED | Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage IA Breast Cancer AJCC v8; Anatomic Stage IB Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage IIA Breast Cancer AJCC v8; Anatomic Stage IIB Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Prognostic Stage I Breast Cancer AJCC v8; Prognostic Stage IA Breast Cancer AJCC v8; Prognostic Stage IB Breast Cancer AJCC v8; Prognostic Stage II Breast Cancer AJCC v8; Prognostic Stage IIA Breast Cancer AJCC v8; Prognostic Stage IIB Breast Cancer AJCC v8; Prognostic Stage III Breast Cancer AJCC v8; Prognostic Stage IIIA Breast Cancer AJCC v8; Prognostic Stage IIIB Breast Cancer AJCC v8; Prognostic Stage IIIC Breast Cancer AJCC v8; Refractory Breast Carcinoma; Triple-Negative Breast Carcinoma |
M.D. Anderson Cancer Center |
2020-07-10 | PHASE2 |
| NCT06199466 | TERMINATED | Metastatic Pancreatic Cancer |
M.D. Anderson Cancer Center |
2024-01-22 | PHASE1 |
| NCT05984602 | ACTIVE_NOT_RECRUITING | Pancreatic Cancer |
NYU Langone Health |
2023-07-14 | PHASE1 |
| NCT06426056 | NOT_YET_RECRUITING | Cervical Cancer |
Peking University Third Hospital |
2024-06 | PHASE2 |
| NCT05374512 | ACTIVE_NOT_RECRUITING | Breast Cancer |
AstraZeneca |
2022-05-16 | PHASE3 |
| NCT06018883 | UNKNOWN | Metastatic Pancreatic Adenocarcinoma |
Fudan University |
2023-08-20 | PHASE3 |
| NCT06051851 | UNKNOWN | Pancreatic Adenocarcinoma Metastatic |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2023-07-01 | PHASE2 |
| NCT05794477 | UNKNOWN | Advanced Solid Tumor |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
2023-04-28 | PHASE1; PHASE2 |
| NCT05328336 | UNKNOWN | Muscle Invasive Bladder Cancer Urothelial Carcinoma |
Tianjin Medical University Second Hospital |
2021-11-11 | PHASE2 |
| NCT05185869 | UNKNOWN | Pancreatic Cancer |
Ruijin Hospital |
2022-01 | PHASE2 |
| NCT04530227 | UNKNOWN | Early Stage Non-small Cell Lung Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2020-09-25 | PHASE2 |
| NCT03918278 | COMPLETED | Neoplasms |
Merck Sharp & Dohme LLC |
2019-06-19 | PHASE1 |
| NCT06080854 | UNKNOWN | Pancreatic Carcinoma |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2023-11-10 | PHASE2 |
| NCT05042128 | UNKNOWN | Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Cancer |
Australasian Gastro-Intestinal Trials Group |
2022-04-13 | PHASE2 |
| NCT05859750 | RECRUITING | Pancreatic Cancer |
Akeso |
2023-05-25 | PHASE2 |
| NCT05908747 | COMPLETED | Pancreatic Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-05-31 | PHASE2 |
| NCT06472037 | UNKNOWN | Locally Advanced Pancreatic Ductal Adenocarcinoma |
Tianjin Medical University Cancer Institute and Hospital |
2024-07-01 | PHASE2 |
| NCT05300048 | TERMINATED | Advanced Solid Tumor; PIK3CA Mutation; PTEN Loss of Function Mutation |
Faeth Therapeutics |
2022-04-22 | PHASE1 |
| NCT04827953 | ACTIVE_NOT_RECRUITING | Pancreatic Ductal Adenocarcinoma |
Nelum Corp |
2021-09-01 | PHASE1; PHASE2 |
| NCT06261359 | RECRUITING | Pancreatic Ductal Adenocarcinoma (PDAC) |
Qilu Pharmaceutical Co., Ltd. |
2024-03-19 | PHASE2 |
| NCT05673811 | COMPLETED | Pancreatic Adenocarcinoma; Metastatic |
Theriva Biologics SL |
2023-01-10 | PHASE2 |
| NCT05257408 | ACTIVE_NOT_RECRUITING | Ovarian Neoplasm; Fallopian Tube Neoplasms; Peritoneal Neoplasms |
Corcept Therapeutics |
2022-06-29 | PHASE3 |
| NCT04469556 | COMPLETED | Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Advanced Pancreatic Cancer |
University Health Network, Toronto |
2020-10-14 | PHASE2 |
| NCT06178211 | NOT_YET_RECRUITING | Esophageal Squamous Cell Carcinoma |
Shanghai Chest Hospital |
2023-12 | PHASE2 |
| NCT04229004 | COMPLETED | Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma |
Pancreatic Cancer Action Network |
2020-01-31 | PHASE3 |
| NCT02344472 | UNKNOWN | Metastatic Breast Cancer |
Prof. Wolfgang Janni |
2015-09 | PHASE3 |
| NCT04222972 | TERMINATED | RET-fusion Non Small Cell Lung Cancer; Lung Neoplasm; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Disease; Carcinoma, Bronchogenic; Bronchial Diseases; Head and Neck Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms by Histologic Type; Neoplasms, Germ Cell and Embryonal; Neoplasms, Nerve Tissue |
Hoffmann-La Roche |
2020-07-24 | PHASE3 |
| NCT05800340 | RECRUITING | Non-Small Cell Lung Cancer; RET Driver Mutation; BRAF V600 Mutation; Erb-B2 Receptor Tyrosine Kinase Exon 20 Mutation; MET Amplification; MET Exon 14 Skipping Mutation |
Guangdong Provincial People's Hospital |
2023-04-04 | PHASE2 |
| NCT04547907 | RECRUITING | Breast Cancer,HER2-positive |
Henan Cancer Hospital |
2020-09-18 | PHASE3 |
| NCT04447092 | UNKNOWN | Pancreatic Cancer; Chemotherapy Effect |
Seoul National University Hospital |
2020-07-01 | PHASE2 |
| NCT05178628 | UNKNOWN | Pancreatic Cancer; Thromboembolism |
Michalis Karamouzis |
2022-02-10 | PHASE3 |
| NCT04675450 | WITHDRAWN | Breast Cancer; Peripheral Neuropathy |
Conjupro Biotherapeutics, Inc. |
2023-06-30 | PHASE2 |
| NCT05728268 | RECRUITING | Breast Cancer |
Shantou Central Hospital |
2021-08-01 | PHASE2 |
| NCT05757336 | RECRUITING | Gallbladder Cancer; Initially Unresectable; the First Line Treatment |
Lu Wang, MD, PhD |
2022-12-22 | PHASE2 |
| NCT04148911 | COMPLETED | Triple-Negative Breast Cancer |
Hoffmann-La Roche |
2019-12-10 | PHASE3 |
| NCT04666688 | COMPLETED | Metastatic Cancer; Solid Tumor; Pancreatic Cancer; Urothelial Carcinoma; Head and Neck Cancer; Colorectal Cancer |
PureTech |
2020-12-15 | PHASE1; PHASE2 |
| NCT05633914 | UNKNOWN | HR+/HER2- Breast Cancer |
Hunan Cancer Hospital |
2023-02-07 | PHASE2 |
| NCT06016413 | NOT_YET_RECRUITING | Head and Neck Squamous Cell Carcinoma |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2023-09-01 | PHASE2 |
| NCT04876313 | UNKNOWN | Muscle-Invasive Bladder Carcinoma |
IRCCS San Raffaele |
2022-01-27 | PHASE2 |
| NCT05664139 | UNKNOWN | Malignant Melanoma; Liver Metastases |
Fujian Cancer Hospital |
2023-02 | PHASE2 |
| NCT02945800 | COMPLETED | Osteosarcoma; Ewing Sarcoma; Rhabdomyosarcoma; Soft Tissue Sarcoma |
H. Lee Moffitt Cancer Center and Research Institute |
2016-10-25 | PHASE2 |
| NCT04787991 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Cancer Insight, LLC |
2021-08-09 | PHASE1 |
| NCT03750669 | COMPLETED | Pancreatic Adenocarcinoma Resectable; Neoadjuvant Chemotherapy |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2018-10-20 | PHASE3 |
| NCT05832892 | UNKNOWN | Unresectable Locally Advanced or Metastatic Pancreatic Cancer |
Shanghai Zhongshan Hospital |
2023-11-01 | PHASE1; PHASE2 |
| NCT04958785 | TERMINATED | Triple-Negative Breast Cancer |
Gilead Sciences |
2021-12-14 | PHASE2 |
| NCT04999969 | ACTIVE_NOT_RECRUITING | Locally Advanced or Metastatic Solid Tumours |
AstraZeneca |
2021-12-10 | PHASE2 |
| NCT06538207 | COMPLETED | Metastatic Pancreatic Cancer |
Ono Pharmaceutical Co., Ltd. |
2021-01-13 | PHASE1 |
| NCT04672005 | UNKNOWN | Metastatic Pancreatic Cancer |
Lyudmyla Berim |
2021-01-06 | PHASE2 |
| NCT05226598 | COMPLETED | Metastatic Non-Small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2022-03-24 | PHASE3 |
| NCT02258659 | COMPLETED | Human Papilloma Virus Infection; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage IVA Squamous Cell Carcinoma of the Oropharynx; Stage IVB Squamous Cell Carcinoma of the Oropharynx |
University of Chicago |
2014-09-22 | PHASE2 |
| NCT03107182 | COMPLETED | HPV-Related Squamous Cell Carcinoma; HNSCC |
University of Chicago |
2017-06-27 | PHASE2 |
| NCT05253053 | COMPLETED | Advanced Solid Tumor; Cholangiocarcinoma; Biliary Tract Cancer; HER2-negative Breast Cancer; Triple Negative Breast Cancer; Small-cell Lung Cancer; Bladder Cancer; Prostate Cancer; Thyroid Cancer; Gastric Cancer; Gallbladder Cancer |
TransThera Sciences (Nanjing), Inc. |
2022-04-13 | PHASE1; PHASE2 |
| NCT02672917 | TERMINATED | Pancreatic Cancer |
BioNTech Research & Development, Inc. |
2016-01 | PHASE1 |
| NCT04047862 | COMPLETED | Locally Advanced and Metastatic Solid Tumors |
BeiGene |
2019-08-15 | PHASE1 |
| NCT04715542 | Not yet recruiting | Chemotherapy Induced Peripheral Neuropathy (CIPN) |
University of Bern|Insel Gruppe AG University Hospital Bern|Hospital of Thun|Tumor- und Brustzentrum ZeTuP St.Gallen|Gesundheitszentrum Fricktal AG|Kantonsspital Winterthur KSW|Kantonsspital Graubünden|Kantonsspital Aarau |
2024-08 | Phase 3 |
| NCT04554524 | UNKNOWN | Thymoma and Thymic Carcinoma |
Tang-Du Hospital |
2020-08-27 | PHASE4 |
| NCT04734262 | UNKNOWN | Metastatic Breast Cancer |
Fudan University |
2021-04-01 | PHASE2 |
| NCT05761470 | RECRUITING | Her-2 Negative Breast Cancer; HRR Gene Mutation |
Ying Lin |
2022-05-06 | PHASE2 |
| NCT04643405 | TERMINATED | Advanced Pancreatic Cancer |
Ascentage Pharma Group Inc. |
2021-03-17 | PHASE1; PHASE2 |
| NCT03941093 | COMPLETED | Pancreatic Cancer Non-resectable |
Kyntra Bio |
2019-05-10 | PHASE3 |
| NCT05244213 | UNKNOWN | Non-small Cell Lung Cancer; EGFR Activating Mutation |
Guangdong Provincial People's Hospital |
2022-06-04 | PHASE2 |
| NCT02481635 | COMPLETED | Pancreatic Cancer |
University Health Network, Toronto |
2016-12-08 | PHASE1; PHASE2 |
| NCT04247165 | COMPLETED | Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer |
Herlev Hospital |
2020-06-02 | PHASE1; PHASE2 |
| NCT04289792 | UNKNOWN | Pancreatic Neoplasms |
Fujian Medical University Union Hospital |
2020-05-09 | PHASE2 |
| NCT04390763 | TERMINATED | Metastatic Pancreatic Ductal Adenocarcinoma |
Novartis Pharmaceuticals |
2020-10-16 | PHASE2 |
| NCT05611879 | UNKNOWN | NSCLC, Stage III |
Beijing Tsinghua Chang Gung Hospital |
2023-03-12 | PHASE2 |
| NCT05429684 | UNKNOWN | HER2+ Breast Cancer |
First Affiliated Hospital Xi'an Jiaotong University |
2021-01-01 | PHASE3 |
| NCT04742959 | COMPLETED | Advanced Solid Tumor; Cholangiocarcinoma; HER2-negative Breast Cancer; Triple Negative Breast Cancer; Bladder Cancer; Small-cell Lung Cancer; Prostate Cancer; Thyroid Cancer; Sarcoma; Gastric Cancer; Gallbladder Cancer |
TransThera Sciences (Nanjing), Inc. |
2021-03-14 | PHASE1; PHASE2 |
| NCT01847326 | COMPLETED | Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Tongue Cancer |
University of Chicago |
2013-03-26 | PHASE1 |
| NCT06199466 | Recruiting | Metastatic Pancreatic Cancer |
M.D. Anderson Cancer Center|280Bio Inc |
2024-01-22 | Phase 1 |
| NCT02620280 | COMPLETED | Invasive Ductal Breast Carcinoma |
Fondazione Michelangelo |
2016-04 | PHASE3 |
| NCT05447702 | RECRUITING | Triple Negative Breast Cancer |
West China Hospital |
2022-11-01 | PHASE2 |
| NCT05640791 | RECRUITING | Resectable Biliary Tract Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2023-01-12 | PHASE2 |
| NCT05052931 | UNKNOWN | Gastric Cancer |
Jianjun Yang |
2021-10-01 | PHASE2 |
| NCT04762030 | UNKNOWN | Non Small Cell Lung Cancer |
Shanghai Pulmonary Hospital, Shanghai, China |
2021-02-08 | PHASE2 |
| NCT04205812 | COMPLETED | Metastatic Squamous Non-Small Cell Lung Cancer; Metastatic Nonsquamous Non-Small Cell Lung Cancer |
Incyte Corporation |
2020-09-11 | PHASE3 |
| NCT04000906 | UNKNOWN | Peritoneal Carcinomatosis |
University Hospital, Geneva |
2020-11-11 | PHASE1 |
| NCT05390710 | COMPLETED | Solid Tumor; TNBC - Triple-Negative Breast Cancer |
Laekna Limited |
2021-06-12 | PHASE1 |
| NCT04807140 | RECRUITING | Head and Neck Squamous Cell Carcinoma |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2021-07-08 | PHASE2 |
| NCT04900311 | UNKNOWN | HER2+ Early or Locally Advanced Breast Cancer |
Tianjin Medical University Cancer Institute and Hospital |
2021-05 | PHASE2 |
| NCT03976362 | COMPLETED | Carcinoma, Squamous Cell, Non-small-cell Lung |
Merck Sharp & Dohme LLC |
2019-06-28 | PHASE3 |
| NCT03579771 | COMPLETED | Resectable Cholangiocarcinoma; Stage IB Intrahepatic Cholangiocarcinoma AJCC v8; Stage II Intrahepatic Cholangiocarcinoma AJCC v8; Stage III Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8; Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 |
Emory University |
2018-09-26 | PHASE2 |
| NCT05670925 | UNKNOWN | Triple-Negative Breast Cancer |
Fudan University |
2023-03-01 | PHASE2 |
| NCT05070598 | UNKNOWN | HER2-positive Gastric Cancer |
Shengjing Hospital |
2021-09-07 | PHASE2 |
| NCT05444998 | UNKNOWN | Breast Cancer |
Xijing Hospital |
2022-11-01 | PHASE2 |
| NCT03961698 | UNKNOWN | Breast Cancer; Renal Cell Carcinoma |
Infinity Pharmaceuticals, Inc. |
2019-12-17 | PHASE2 |
| NCT04877821 | COMPLETED | Triple Negative Breast Cancer |
Guangdong Provincial People's Hospital |
2021-09-15 | PHASE2 |
| NCT04983407 | TERMINATED | Pancreatic Adenocarcinoma |
Aravive, Inc. |
2021-07-28 | PHASE1; PHASE2 |
| NCT06059001 | Recruiting | Metastatic Pancreatic Cancer |
Peptomyc S.L. |
2023-08-31 | Phase 1 |
| NCT05982522 | Not yet recruiting | Solid Tumor |
InxMed (Shanghai) Co. Ltd. |
2023-08 | Phase 1|Phase 2 |
| NCT05562297 | Not yet recruiting | Pancreatic Cancer Stage IB|Pancreatic Cancer Stage IIA|Pancreatic Cancer Stage IIB|Pancreatic Cancer Stage III |
Shanghai Zhongshan Hospital|Fudan University |
2023-07-01 | Phase 2 |
| NCT03361319 | WITHDRAWN | NSCLC, Recurrent; Adenocarcinoma of Lung |
Royal Marsden NHS Foundation Trust |
2020-07 | PHASE1; PHASE2 |
| NCT05410847 | UNKNOWN | Gastric Cancer |
Hebei Medical University |
2022-06-30 | PHASE2 |
| NCT04964960 | TERMINATED | Lung Cancer; Lung Cancer Metastatic; Brain Cancer; Cancer |
John L. Villano, MD, PhD |
2022-05-19 | PHASE2 |
| NCT04524702 | COMPLETED | Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage IV Pancreatic Cancer AJCC v8 |
Emory University |
2020-09-14 | PHASE2 |
| NCT05000892 | RECRUITING | Salivary Gland Malignant Neoplasms; Salivary Gland Tumors |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2021-12-10 | PHASE2 |
| NCT03815461 | UNKNOWN | Locally Advanced Pancreatic Cancer |
Chinese Academy of Medical Sciences |
2019-02-01 | PHASE2 |
| NCT05441254 | UNKNOWN | Stage IV Gastric Cancer With Metastasis |
Zhongshan Hospital Xiamen University |
2022-07 | PHASE2 |
| NCT04395989 | UNKNOWN | TNBC - Triple-Negative Breast Cancer |
Fudan University |
2020-07-28 | PHASE2 |
| NCT05138159 | UNKNOWN | Metastatic Pancreatic Cancer |
Fudan University |
2021-12-01 | PHASE2 |
| NCT03003546 | COMPLETED | Recurrent Aggressive Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Aggressive Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Small Lymphocytic Lymphoma |
Mayo Clinic |
2019-04-25 | PHASE1 |
| NCT03435250 | TERMINATED | Advanced Solid Tumors; Lymphoma |
Institut de Recherches Internationales Servier |
2018-03-04 | PHASE1 |
| NCT04335006 | TERMINATED | Breast Cancer; Triple Negative Breast Cancer |
Jiangsu HengRui Medicine Co., Ltd. |
2020-07-14 | PHASE3 |
| NCT04956692 | ACTIVE_NOT_RECRUITING | Non-Small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2021-08-05 | PHASE3 |
| NCT05634564 | UNKNOWN | Pancreatic Carcinoma |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
2020-06-01 | PHASE2 |
| NCT04826679 | UNKNOWN | Head and Neck Squamous Cell Carcinoma |
Sun Yat-sen University |
2021-04-01 | PHASE2 |
| NCT04584112 | COMPLETED | Triple-Negative Breast Cancer |
Hoffmann-La Roche |
2020-09-28 | PHASE1 |
| NCT04808687 | UNKNOWN | Pancreatic Neoplasms |
Tianjin Medical University Cancer Institute and Hospital |
2021-03 | PHASE2 |
| NCT05251038 | WITHDRAWN | Pancreatic Cancer; Unresectable Pancreatic Cancer; Metastatic Pancreatic Cancer; KRAS P.G12C |
Devalingam Mahalingam |
2022-09-13 | PHASE1; PHASE2 |
| NCT04192331 | UNKNOWN | Breast Cancer |
Peking University Cancer Hospital & Institute |
2019-02-21 | PHASE2 |
| NCT02930902 | COMPLETED | Resectable Pancreatic Carcinoma; Stage I Pancreatic Cancer AJCC v6 and v7; Stage IA Pancreatic Cancer AJCC v6 and v7; Stage IB Pancreatic Cancer AJCC v6 and v7; Stage II Pancreatic Cancer AJCC v6 and v7; Stage IIA Pancreatic Cancer AJCC v6 and v7; Stage IIB Pancreatic Cancer AJCC v6 and v7 |
M.D. Anderson Cancer Center |
2017-02-20 | PHASE1 |
| NCT04718415 | ACTIVE_NOT_RECRUITING | Oral Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2021-01-23 | PHASE2 |
| NCT04745975 | UNKNOWN | Triple Negative Breast Cancer |
Fudan University |
2021-02-01 | PHASE2 |
| NCT04722718 | UNKNOWN | Breast Cancer |
Jiuda Zhao |
2021-02-01 | PHASE2 |
| NCT04850235 | UNKNOWN | Nasopharyngeal Cancer |
Sun Yat-sen University |
2021-04-15 | PHASE1 |
| NCT02788981 | ACTIVE_NOT_RECRUITING | Breast Cancer |
University of Chicago |
2017-03-28 | PHASE2 |
| NCT04258072 | UNKNOWN | Pancreas Cancer |
Samsung Medical Center |
2021-04-19 | PHASE1 |
| NCT03666832 | UNKNOWN | Metastatic Pancreatic Cancer |
Joon Oh Park |
2019-06-17 | PHASE1; PHASE2 |
| NCT04306900 | COMPLETED | Solid Tumor, Adult |
Trishula Therapeutics, Inc. |
2020-03-30 | PHASE1 |
| NCT02999477 | COMPLETED | Breast Cancer |
Adrienne G. Waks |
2017-02-23 | PHASE1 |
| NCT04581343 | COMPLETED | Metastatic Pancreatic Ductal Adenocarcinoma |
Pancreatic Cancer Action Network |
2020-11-02 | PHASE1 |
| NCT04196283 | COMPLETED | Advanced Solid Tumors Cancer |
AbbVie |
2020-01-22 | PHASE1 |
| NCT03535727 | COMPLETED | Adenocarcinoma; Pancreatic Neoplasms; Neoplasm, Glandular; Neoplasms; Neoplasms Pancreatic; Digestive System Neoplasm; Endocrine Gland Neoplasms; Digestive System Disease; Pancreatic Diseases; Endocrine System Diseases |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2018-06-21 | PHASE1; PHASE2 |
| NCT01676259 | UNKNOWN | Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer |
Silenseed Ltd |
2018-03-07 | PHASE2 |
| NCT04422392 | TERMINATED | Non Small Cell Lung Cancer |
Shanghai Pulmonary Hospital, Shanghai, China |
2020-07-13 | PHASE2 |
| NCT02426281 | COMPLETED | Pancreatic Ductal Adenocarcinoma |
Samsung Medical Center |
2015-06-04 | PHASE2 |
| NCT03928314 | TERMINATED | Solid Tumor |
ORIC Pharmaceuticals |
2019-05-02 | PHASE1 |
| NCT04129996 | UNKNOWN | Triple-Negative Breast Cancer |
Fudan University |
2019-10-01 | PHASE2 |
| NCT03872791 | COMPLETED | Triple-negative Breast Cancer |
Jiangsu Alphamab Biopharmaceuticals Co., Ltd |
2019-05-30 | PHASE1; PHASE2 |
| NCT04195828 | COMPLETED | Advanced Gastric Cancer |
Fujian Medical University |
2020-06-18 | PHASE2 |
| NCT03910387 | COMPLETED | Locally Advanced Unresectable Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Recurrent Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 |
Emory University |
2019-04-17 | PHASE2 |
| NCT03745430 | COMPLETED | Pancreatic Adenocarcinoma |
Hellenic Cooperative Oncology Group |
2019-01-29 | PHASE1; PHASE2 |
| NCT04825938 | NOT_YET_RECRUITING | Salivary Gland Malignant Neoplasms; Salivary Gland Tumors |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2021-04-30 | PHASE2 |
| NCT04390958 | UNKNOWN | Esophageal Squamous Cell Carcinoma |
Chinese Academy of Medical Sciences |
2020-05-15 | PHASE2 |
| NCT04659499 | UNKNOWN | Early Breast Cancer |
Peking Union Medical College Hospital |
2021-01 | PHASE2 |
| NCT04481009 | COMPLETED | Advanced Solid Tumors |
Eucure (Beijing) Biopharma Co., Ltd |
2020-08-04 | PHASE1; PHASE2 |
| NCT03519308 | TERMINATED | Pancreatic Cancer |
Abramson Cancer Center at Penn Medicine |
2020-07-29 | EARLY_PHASE1 |
| NCT04405674 | UNKNOWN | Non Small Cell Lung Cancer |
Shanghai Chest Hospital |
2020-07-15 | PHASE2 |
| NCT04652206 | UNKNOWN | Metastatic Pancreatic Adenocarcinoma; Locally Advanced Pancreatic Adenocarcinoma; Inoperable Disease; Localized Pancreatic Adenocarcinoma |
Scandion Oncology A/S |
2020-10-27 | PHASE1; PHASE2 |
| NCT03800836 | COMPLETED | Breast Cancer |
Hoffmann-La Roche |
2018-02-13 | PHASE1 |
| NCT04826016 | WITHDRAWN | Advanced Breast Cancer |
MedSIR |
2022-03-16 | PHASE1; PHASE2 |
| NCT03885219 | UNKNOWN | Locally Advanced Pancreatic Cancer |
Peking Union Medical College Hospital |
2019-05-01 | PHASE2 |
| NCT02564146 | COMPLETED | Metastatic Pancreatic Cancer; Adenocarcinoma of the Pancreas |
AIO-Studien-gGmbH |
2016-12 | PHASE2 |
| NCT03850769 | UNKNOWN | Borderline Resectable Pancreatic Cancer |
Peking Union Medical College Hospital |
2019-05-01 | PHASE2 |
| NCT03412799 | COMPLETED | Pancreatic Cancer Metastatic; Pancreatic Cancer Stage IV; Stage IV Pancreatic Cancer |
Panbela Therapeutics, Inc. |
2018-06-04 | PHASE1 |
| NCT03174275 | ACTIVE_NOT_RECRUITING | Carcinoma, Squamous Cell; Oral Cancer; Oropharynx Cancer; Larynx Cancer; Lip Cancer; Esophageal Cancer |
UNC Lineberger Comprehensive Cancer Center |
2017-12-19 | PHASE2 |
| NCT04211012 | UNKNOWN | Urothelial Carcinoma |
Jun Guo |
2020-11-30 | PHASE2 |
| NCT04037241 | WITHDRAWN | Malignant Tumor of Pancreas Metastatic to Liver |
Sorrento Therapeutics, Inc. |
2021-11-01 | PHASE2; PHASE3 |
| NCT02229149 | TERMINATED | Breast Neoplasms; Malignant Tumor of the Breast |
US Oncology Research |
2014-12 | PHASE2 |
| NCT04707118 | UNKNOWN | Advanced Pancreatic Cancer |
Fudan University |
2021-02-23 | PHASE1 |
| NCT02684461 | COMPLETED | Non Small Cell Lung Cancer |
UNC Lineberger Comprehensive Cancer Center |
2016-09-13 | PHASE2 |
| NCT03496662 | COMPLETED | Pancreatic Ductal Adenocarcinoma |
Washington University School of Medicine |
2018-08-31 | PHASE1; PHASE2 |
| NCT03275818 | COMPLETED | Tumor, Desmoplastic Small Round Cell, Adult; Tumor, Desmoplastic Small Round Cell, Childhood; Sarcoma, Ewing; Sarcoma; Desmoid |
Grupo Espanol de Investigacion en Sarcomas |
2017-05-09 | PHASE2 |
| NCT03703063 | UNKNOWN | Pancreatic Adenocarcinoma |
Benaroya Research Institute |
2018-09-17 | PHASE1 |
| NCT02926183 | UNKNOWN | Pancreatic Ductal Adenocarcinoma |
Wakayama Medical University |
2016-10 | PHASE2 |
| NCT02767557 | COMPLETED | Unresectable Pancreatic Carcinoma |
Herlev Hospital |
2017-01-26 | PHASE2 |
| NCT02550327 | COMPLETED | Pancreatic Adenocarcinoma |
Baylor Research Institute |
2016-01 | EARLY_PHASE1 |
| NCT03162510 | COMPLETED | Gastric Cancer in Situ; Pancreatic Cancers; Biliary Cancers |
National Health Research Institutes, Taiwan |
2018-06-26 | PHASE1 |
| NCT02194829 | COMPLETED | Metastatic Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v6 and v7; Stage IV Pancreatic Cancer AJCC v6 and v7; Unresectable Pancreatic Carcinoma |
National Cancer Institute (NCI) |
2014-08-19 | PHASE1; PHASE2 |
| NCT03959397 | UNKNOWN | Breast Cancer Stage |
Jilin University |
2019-06-01 | PHASE2 |
| NCT02718742 | WITHDRAWN | Recurrent Bladder Urothelial Carcinoma; Stage IV Bladder Urothelial Carcinoma |
Mayo Clinic |
2016-06 | PHASE2 |
| NCT04299880 | COMPLETED | Oncology |
Sumitomo Pharma America, Inc. |
2020-02-24 | PHASE1 |
| NCT02607202 | COMPLETED | Unknown Primary Tumors |
Fondazione del Piemonte per l'Oncologia |
2015-03 | PHASE2 |
| NCT04067102 | WITHDRAWN | Triple Negative Breast Cancer |
Hebei Medical University Fourth Hospital |
2019-05-10 | |
| NCT02504333 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) |
2015-07 | PHASE1; PHASE2 |
| NCT02710396 | TERMINATED | Carcinoma, Non-Small-Cell Lung |
Columbia University |
2016-05-31 | PHASE2 |
| NCT03655080 | TERMINATED | Cord Compression |
Washington University School of Medicine |
2019-01-09 | PHASE2 |
| NCT03214250 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Parker Institute for Cancer Immunotherapy |
2017-07-21 | PHASE1; PHASE2 |
| NCT01730833 | COMPLETED | HER2-positive Breast Cancer; Recurrent Breast Cancer; Stage IIA Breast Cancer; Stage IIB Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Breast Adenocarcinoma; Inflammatory Breast Carcinoma |
City of Hope Medical Center |
2013-07-17 | PHASE2 |
| NCT03775486 | ACTIVE_NOT_RECRUITING | Non-small Cell Lung Cancer NSCLC |
AstraZeneca |
2018-12-21 | PHASE2 |
| NCT03086369 | COMPLETED | Metastatic Pancreatic Cancer |
Eli Lilly and Company |
2017-06-22 | PHASE1; PHASE2 |
| NCT03779464 | UNKNOWN | Pancreatic Cancer; Nab-paclitaxel; Gemcitabine; S1 |
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
2019-08-01 | PHASE2 |
| NCT04015661 | UNKNOWN | Nasopharyngeal Carcinoma |
Fuzhou General Hospital |
2019-07-09 | PHASE2 |
| NCT03316599 | COMPLETED | Pancreatic Cancer |
Dana-Farber Cancer Institute |
2018-01-17 | PHASE1 |
| NCT03594747 | COMPLETED | Non-Small Cell Lung Cancer |
BeiGene |
2018-07-30 | PHASE3 |
| NCT04077983 | UNKNOWN | Cholangiocarcinoma, Intrahepatic |
Shanghai Zhongshan Hospital |
2019-09-01 | PHASE2 |
| NCT04004234 | UNKNOWN | Biliary Tract Cancer (BTC) |
Chinese PLA General Hospital |
2019-03-01 | PHASE1; PHASE2 |
| NCT03289819 | COMPLETED | Malignant Neoplasm of Breast |
Institut fuer Frauengesundheit |
2018-03-23 | PHASE2 |
| NCT02392637 | COMPLETED | Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Extrahepatic Bile Duct Carcinoma; Unresectable Gallbladder Carcinoma |
M.D. Anderson Cancer Center |
2015-04-02 | PHASE2 |
| NCT02879318 | COMPLETED | Pancreatic Adenocarcinoma |
Canadian Cancer Trials Group |
2016-11-07 | PHASE2 |
| NCT03636308 | UNKNOWN | Pancreatic Cancer |
Peking University |
2018-07-17 | PHASE2 |
| NCT03600623 | TERMINATED | Locally Advanced Pancreatic Cancer; Borderline Pancreatic Inoperable Cancer; Pancreatic Cancer |
University of Alabama at Birmingham |
2017-09-25 | EARLY_PHASE1 |
| NCT04148885 | UNKNOWN | Castration-resistant Prostate Cancer |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2019-11 | PHASE1; PHASE2 |
| NCT03517176 | COMPLETED | Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma |
Lisata Therapeutics, Inc. |
2018-07-31 | PHASE1 |
| NCT02762981 | COMPLETED | Solid Tumors |
Corcept Therapeutics |
2016-05-23 | PHASE1; PHASE2 |
| NCT04066790 | TERMINATED | Breast Cancer |
Shanghai Jiao Tong University School of Medicine |
2019-09-09 | PHASE2 |
| NCT03919253 | UNKNOWN | HER2-positive Breast Cancer |
Hebei Medical University Fourth Hospital |
2019-04-30 | PHASE2 |
| NCT03193853 | COMPLETED | Triple Negative Breast Cancer |
Joyce O'Shaughnessy |
2017-07-18 | PHASE2 |
| NCT02993731 | COMPLETED | Carcinoma, Pancreatic Ductal |
Sumitomo Pharma America, Inc. |
2016-12 | PHASE3 |
| NCT01840579 | COMPLETED | Solid Tumor; Non-small Cell Lung Cancer; Small Cell Lung Cancer |
Merck Sharp & Dohme LLC |
2013-04-26 | PHASE1 |
| NCT02812992 | COMPLETED | Adenocarcinoma Pancreas |
AIO-Studien-gGmbH |
2016-06 | PHASE4 |
| NCT03777579 | SUSPENDED | Triple Negative Breast Cancer |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2018-12-21 | PHASE3 |
| NCT03563144 | WITHDRAWN | Metastatic Pancreatic Cancer |
ImmunityBio, Inc. |
2018-08 | PHASE2 |
| NCT02562898 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Margaret Tempero |
2015-10-12 | PHASE1; PHASE2 |
| NCT02427841 | COMPLETED | Pancreatic Adenocarcinoma; Resectable Pancreatic Carcinoma |
OHSU Knight Cancer Institute |
2016-01-21 | PHASE2 |
| NCT03262948 | UNKNOWN | Non-small Cell Lung Cancer |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2017-12-01 | PHASE3 |
| NCT01572038 | COMPLETED | Breast Neoplasms |
Hoffmann-La Roche |
2012-06-01 | PHASE3 |
| NCT02730247 | COMPLETED | Non-small Cell Lung Cancer |
Liza Villaruz, MD |
2017-07-05 | PHASE2 |
| NCT01757288 | COMPLETED | STAGE IIIA/B NSCLC / INOPERABLE LUNG CANCER |
University of Texas Southwestern Medical Center |
2013-03-25 | PHASE1; PHASE2 |
| NCT03051373 | COMPLETED | Carcinoma, Transitional Cell |
Chinese PLA General Hospital |
2017-04-01 | PHASE2 |
| NCT03344172 | TERMINATED | Pancreatic Cancer Resectable |
Nathan Bahary, MD |
2017-12-13 | PHASE2 |
| NCT03387111 | TERMINATED | Squamous Cell Carcinoma |
ImmunityBio, Inc. |
2018-01-09 | PHASE1; PHASE2 |
| NCT02608229 | TERMINATED | Pancreatic Cancer; Cancer of Pancreas; Cancer of the Pancreas; Pancreas Cancer |
Washington University School of Medicine |
2016-06-06 | PHASE1 |
| NCT03307148 | COMPLETED | Pancreatic Adenocarcinoma |
Barts & The London NHS Trust |
2016-01-15 | PHASE1 |
| NCT03085914 | COMPLETED | Solid Tumor |
Incyte Corporation |
2017-05-02 | PHASE1; PHASE2 |
| NCT01525966 | ACTIVE_NOT_RECRUITING | Inflammatory Breast Cancer; Stage IIA Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer; Stage IIB Breast Cancer; Estrogen Receptor Negative; Progesterone Receptor Negative; HER2/Neu Negative |
City of Hope Medical Center |
2012-02-15 | PHASE2 |
| NCT02810418 | COMPLETED | Neoplasms; Pancreatic Neoplasms |
National Cancer Institute (NCI) |
2016-08-03 | PHASE1; PHASE2 |
| NCT03401827 | UNKNOWN | Pancreatic Adenocarcinoma; Chemotherapy Effect |
Seoul National University Hospital |
2018-03-01 | PHASE4 |
| NCT03197571 | WITHDRAWN | Urothelial Carcinoma |
ImmunityBio, Inc. |
2017-12 | PHASE1; PHASE2 |
| NCT03169777 | WITHDRAWN | Colorectal Cancer |
ImmunityBio, Inc. |
2018-08 | PHASE1; PHASE2 |
| NCT03169764 | WITHDRAWN | Head and Neck Squamous Cell Carcinoma |
ImmunityBio, Inc. |
2017-12 | PHASE1; PHASE2 |
| NCT03167177 | WITHDRAWN | Melanoma |
ImmunityBio, Inc. |
2017-12 | PHASE1; PHASE2 |
| NCT02506842 | UNKNOWN | Stage ⅠA Pancreatic Cancer; Stage ⅠB Pancreatic Cancer; Stage ⅡA Pancreatic Cancer; Stage ⅡB Pancreatic Cancer |
Fudan University |
2015-06 | PHASE3 |
| NCT02975141 | UNKNOWN | Metastatic Pancreatic Cancer |
PD Dr. med. Volker Heinemann |
2016-09 | PHASE1 |
| NCT01583426 | COMPLETED | Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer |
GBG Forschungs GmbH |
2012-07 | PHASE3 |
| NCT02215447 | UNKNOWN | Gastrointestinal Neuroendocrine Carcinomas |
Barwon Health |
2015-05 | PHASE2 |
| NCT02436668 | COMPLETED | Metastatic Pancreatic Adenocarcinoma |
Pharmacyclics LLC. |
2015-05 | PHASE3 |
| NCT01690702 | COMPLETED | Breast Cancer |
GBG Forschungs GmbH |
2012-09 | PHASE3 |
| NCT03387098 | TERMINATED | Pancreatic Cancer |
ImmunityBio, Inc. |
2017-12-28 | PHASE1; PHASE2 |
| NCT03830606 | COMPLETED | Biliary Tract Cancer |
Aiping Zhou |
2016-03-23 | PHASE2 |
| NCT02574663 | COMPLETED | Pancreatic Cancer; Colorectal Cancer; Rectal Cancer; Gastric Cancer; Esophageal Cancer; Gastrointestinal Stromal Tumor (GIST) |
TG Therapeutics, Inc. |
2015-09-11 | PHASE1 |
| NCT03574649 | WITHDRAWN | Non Small Cell Lung Cancer |
ImmunityBio, Inc. |
2018-06 | PHASE2 |
| NCT02023021 | COMPLETED | Stage IA Pancreatic Adenocarcinoma; Stage IB Pancreatic Adenocarcinoma; Stage IIA Pancreatic Adenocarcinoma; Stage IIB Pancreatic Adenocarcinoma |
Xian-Jun Yu |
2014-01 | PHASE2 |
| NCT02622074 | COMPLETED | Triple Negative Breast Neoplasms |
Merck Sharp & Dohme LLC |
2016-01-27 | PHASE1 |
| NCT02487277 | TERMINATED | Adenocarcinoma |
Andrew Ko |
2015-07-14 | PHASE2 |
| NCT02283372 | COMPLETED | Pancreatic Cancer |
Washington University School of Medicine |
2015-01-21 | PHASE1 |
| NCT01839487 | COMPLETED | Metastatic Pancreatic Cancer |
Halozyme Therapeutics |
2013-05-14 | PHASE2 |
| NCT01493310 | COMPLETED | Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer |
University of Chicago |
2011-11 | PHASE1 |
| NCT02685059 | COMPLETED | Breast Cancer |
GBG Forschungs GmbH |
2016-06 | PHASE2 |
| NCT02559674 | COMPLETED | Advanced Pancreatic Cancer |
Altor BioScience |
2016-07 | PHASE1 |
| NCT01376310 | TERMINATED | Cancer |
Novartis Pharmaceuticals |
2010-11-02 | PHASE2 |
| NCT02077881 | COMPLETED | Metastatic Pancreatic Adenocarcinoma; Metastatic Pancreatic Cancer |
NewLink Genetics Corporation |
2014-08 | PHASE1; PHASE2 |
| NCT02331251 | TERMINATED | Advanced Cancer; Breast Cancer; Sarcoma; Pancreatic Cancer; Small Cell Lung Cancer; Ovarian |
Western Regional Medical Center |
2014-12 | PHASE1; PHASE2 |
| NCT02967133 | TERMINATED | Non-Small-Cell Lung Cancer Metastatic; Non-Small Cell Carcinoma of Lung, TNM Stage 4; Nonsmall Cell Lung Cancer; Non Small Cell Lung Cancer Recurrent |
Alliance Foundation Trials, LLC. |
2016-12 | PHASE2 |
| NCT01088815 | COMPLETED | Metastatic Pancreatic Cancer |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2010-09-17 | PHASE2 |
| NCT02827201 | COMPLETED | Metastatic Pancreatic Cancer |
Federation Francophone de Cancerologie Digestive |
2015-11 | PHASE2 |
| NCT01971281 | UNKNOWN | Pancreatic Adenocarcinoma |
NovoCure Ltd. |
2013-11 | PHASE1; PHASE2 |
| NCT02707328 | TERMINATED | Pancreas Cancer; Pancreatic Cancer; Adenocarcinoma of the Pancreas; Pancreas Adenocarcinoma; Pancreatic Adenocarcinoma |
The Cooper Health System |
2015-01 | PHASE1 |
| NCT02005315 | COMPLETED | Pancreatic Cancer; Stage IV Pancreatic Cancer |
OncoMed Pharmaceuticals, Inc. |
2013-09 | PHASE1 |
| NCT02783222 | COMPLETED | Breast Cancer |
Fondazione Sandro Pitigliani |
2013-01-30 | PHASE2 |
| NCT02732938 | TERMINATED | Metastatic Pancreatic Ductal Adenocarcinoma |
Pfizer |
2016-05-04 | PHASE2 |
| NCT02027428 | COMPLETED | Squamous Cell Carcinoma, Non-Small-Cell Lung |
Celgene |
2014-02-11 | PHASE3 |
| NCT02151149 | COMPLETED | Non-Small Cell Lung Cancer; Carcinoma; Squamous Cell Carcinoma; Adenocarcinoma; Carcinoma, Large Cell; Lung Neoplasm |
Celgene |
2014-06-09 | PHASE4 |
| NCT00733408 | COMPLETED | Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer |
University of Washington |
2008-04-23 | PHASE2 |
| NCT01702844 | COMPLETED | Non Small Cell Lung Cancer (NSCLC) |
UNC Lineberger Comprehensive Cancer Center |
2013-06-25 | PHASE2 |
| NCT02328105 | COMPLETED | Lung Cancer |
Wake Forest University Health Sciences |
2014-12 | PHASE2 |
| NCT02506803 | UNKNOWN | Pancreatic Cancer |
Wakayama Medical University |
2015-07 | PHASE1 |
| NCT01463072 | ACTIVE_NOT_RECRUITING | Locally Advanced Breast Carcinoma; Metastatic Breast Carcinoma; Recurrent Breast Carcinoma; Stage III Breast Cancer AJCC v7; Stage IIIA Breast Cancer AJCC v7; Stage IIIB Breast Cancer AJCC v7; Stage IIIC Breast Cancer AJCC v7; Stage IV Breast Cancer AJCC v6 and v7 |
City of Hope Medical Center |
2012-06-19 | PHASE2 |
| NCT02514421 | COMPLETED | Pancreatic Adenocarcinoma |
The University of Texas Health Science Center, Houston |
2015-07 | PHASE1 |
| NCT01834235 | TERMINATED | Pancreatic Cancer, Adult |
Precision Biologics, Inc |
2013-04 | PHASE1; PHASE2 |
| NCT02273713 | COMPLETED | Esophageal Cancer; Toxicity |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2014-10 | PHASE1; PHASE2 |
| NCT02289456 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Celgene |
2015-04-28 | PHASE2 |
| NCT02651727 | TERMINATED | Pancreatic Cancer |
Verastem, Inc. |
2015-09 | PHASE1 |
| NCT02124317 | UNKNOWN | Advanced Pancreatic Cancer |
Chinese PLA General Hospital |
2014-04 | PHASE2 |
| NCT02019277 | COMPLETED | Breast Cancer |
Hoffmann-La Roche |
2013-12-05 | PHASE3 |
| NCT01881230 | COMPLETED | Breast Tumor; Breast Cancer; Cancer of the Breast; Estrogen Receptor- Negative Breast Cancer; HER2- Negative Breast Cancer; Progesterone Receptor- Negative Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer; Triple-negative Metastatic Breast Cancer; Metastatic Breast Cancer |
Celgene |
2013-09-26 | PHASE2; PHASE3 |
| NCT02174887 | COMPLETED | Pancreatic Adenocarcinoma |
Institut Paoli-Calmettes |
2014-09 | PHASE1 |
| NCT02590003 | TERMINATED | Carcinoma, Non-small Cell Lung |
Yale University |
2015-11 | PHASE2 |
| NCT01836432 | TERMINATED | Pancreatic Cancer; Pancreatic Carcinoma Non-resectable; Locally Advanced Malignant Neoplasm |
NewLink Genetics Corporation |
2013-05 | PHASE3 |
| NCT01494415 | UNKNOWN | Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell |
First People's Hospital of Hangzhou |
2012-07 | PHASE2 |
| NCT02243007 | TERMINATED | Resectable Pancreatic Cancer; Pancreatic Ductal Carcinoma |
Massachusetts General Hospital |
2014-09 | PHASE2 |
| NCT02276560 | TERMINATED | Stage IIIA Non-Small Cell Lung Cancer |
UNC Lineberger Comprehensive Cancer Center |
2015-01 | PHASE2 |
| NCT01746225 | COMPLETED | Metastatic Breastcancer |
ETOP IBCSG Partners Foundation |
2013-04 | PHASE2 |
| NCT02468557 | TERMINATED | Previously Untreated Pancreatic Ductal Adenocarcinoma; Relapsed/Refractory Pancreatic Ductal Adenocarcinoma |
Gilead Sciences |
2015-07-30 | PHASE1 |
| NCT01893801 | COMPLETED | Stage IV Pancreatic Cancer |
Pancreatic Cancer Research Team |
2013-05 | PHASE1; PHASE2 |
| NCT02570711 | TERMINATED | Metastatic Pancreatic Cancer |
Acerta Pharma BV |
2015-10-13 | PHASE2 |
| NCT02267707 | TERMINATED | Pancreatic Neoplasms; Cholestasis |
Celgene |
2015-05-27 | PHASE1 |
| NCT01858883 | COMPLETED | Solid Tumors; Pancreatic Cancer |
Incyte Corporation |
2013-06 | PHASE1; PHASE2 |
| NCT02034968 | WITHDRAWN | Stage IV Esophageal Squamous Cell Carcinoma |
Zhejiang University |
2014-02 | PHASE2 |
| NCT02262897 | UNKNOWN | Small Cell Lung Cancer |
Tongji University |
2013-09 | PHASE2 |
| NCT01763710 | COMPLETED | Breast Cancer |
Fundacion Oncosur |
2012-12 | PHASE2 |
| NCT02075021 | TERMINATED | Relapsed or Refractory Multiple Myeloma |
NYU Langone Health |
2014-03 | PHASE1; PHASE2 |
| NCT02272738 | COMPLETED | Pancreatic Cancer |
Osaka Medical Center for Cancer and Cardiovascular Diseases |
2013-08 | PHASE1 |
| NCT01715142 | COMPLETED | Pancreatic Adenocarcinoma Resectable; Pancreatic Adenocarcinoma Locally Advanced; Pancreatic Adenocarcinoma Metastatic |
Jean-Luc Van Laethem |
2013-03-21 | EARLY_PHASE1 |
| NCT01830244 | UNKNOWN | Breast Cancer |
Barwon Health |
2013-04 | PHASE2 |
| NCT01488552 | COMPLETED | Stage IV Pancreatic Cancer |
Pancreatic Cancer Research Team |
2011-11 | PHASE1; PHASE2 |
| NCT01412229 | COMPLETED | Head and Neck Cancer |
UNC Lineberger Comprehensive Cancer Center |
2012-02 | PHASE2 |
| NCT00642759 | COMPLETED | Non-small Cell Lung Cancer |
Massachusetts General Hospital |
2008-04 | PHASE2 |
| NCT01815242 | COMPLETED | Breast Cancer |
Women's Cancer Study Group GmbH |
2013-06 | PHASE2 |
| NCT02064829 | COMPLETED | Metastatic Breast Cancer; Locally Recurrent Breast Cancer |
Sorrento Therapeutics, Inc. |
2014-03 | |
| NCT02065466 | WITHDRAWN | Metastatic Melanoma; Brain Metastases |
University of Arizona |
2014-07 | PHASE1; PHASE2 |
| NCT01851174 | TERMINATED | Pancreatic Carcinoma Non-resectable; Stage IV Pancreatic Cancer |
Western Regional Medical Center |
2013-02 | PHASE2 |
| NCT02109445 | TERMINATED | Metastatic Cancer Pancreas |
Pfizer |
2014-09-03 | PHASE2 |
| NCT00833807 | COMPLETED | Melanoma; Liver Metastasis |
M.D. Anderson Cancer Center |
2009-02 | PHASE1 |
| NCT01677559 | COMPLETED | Adenocarcinoma; Pancreatic Neoplasms |
Washington University School of Medicine |
2013-05-07 | PHASE1 |
| NCT00944047 | COMPLETED | Breast Cancer |
University of Kansas Medical Center |
2009-07 | PHASE2 |
| NCT01933061 | WITHDRAWN | Metastatic Melanoma |
Celgene Corporation |
2014-01 | PHASE2 |
| NCT00785291 | COMPLETED | Estrogen Receptor Negative; Estrogen Receptor Positive; HER2/Neu Negative; HER2/Neu Positive; Progesterone Receptor Negative; Progesterone Receptor Positive; Recurrent Breast Carcinoma; Stage IIIC Breast Cancer AJCC v6; Stage IV Breast Cancer AJCC v6 and v7 |
National Cancer Institute (NCI) |
2008-10-13 | PHASE3 |
| NCT01298011 | COMPLETED | Resectable Pancreatic Cancer |
Pancreatic Cancer Research Team |
2011-05 | PHASE2 |
| NCT01236716 | COMPLETED | Carcinoma, Non-Small-Cell Lung |
Chinese Society of Lung Cancer |
2010-11 | PHASE2 |
| NCT01432223 | COMPLETED | Breast Cancer; HER-2 Positive Breast Cancer; Effects of Chemotherapy |
Osaka Medical College |
2011-09 | PHASE2 |
| NCT01192165 | COMPLETED | Cancer |
GlaxoSmithKline |
2010-09-14 | PHASE1 |
| NCT00851877 | COMPLETED | Head and Neck Cancer |
University of Texas Southwestern Medical Center |
2009-03-01 | PHASE1; PHASE2 |
| NCT00254592 | COMPLETED | Breast Cancer |
University of California, Irvine |
2005-10 | PHASE2 |
| NCT00983424 | COMPLETED | Metastatic Breast Cancer |
Northwestern University |
2010-02 | PHASE1 |
| NCT01461915 | TERMINATED | Metastatic Pancreatic Cancer |
Jazz Pharmaceuticals |
2011-11 | PHASE2 |
| NCT01161186 | COMPLETED | Pancreatic Neoplasms; Pancreatic Cancer; Adenocarcinoma |
University of California, San Francisco |
2010-07 | PHASE1 |
| NCT00738361 | COMPLETED | Intraocular Melanoma |
Ohio State University Comprehensive Cancer Center |
2008-08 | PHASE2 |
| NCT01442974 | COMPLETED | Pancreatic Cancer |
Grupo Hospital de Madrid |
2011-01 | |
| NCT00609791 | ACTIVE_NOT_RECRUITING | Breast Cancer |
City of Hope Medical Center |
2008-02-11 | PHASE2 |
| NCT00709761 | COMPLETED | Neoplasms, Breast |
Novartis Pharmaceuticals |
2008-07-02 | PHASE2 |
| NCT00629499 | COMPLETED | Breast Cancer |
SCRI Development Innovations, LLC |
2008-04 | PHASE2 |
| NCT00499291 | WITHDRAWN | Cancer |
Eastern Cooperative Oncology Group |
2006-09 |
(data from https://clinicaltrials.gov, updated on 2026-09-04)
Check the
Nab-Paclitaxel
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
- Nab-Paclitaxel Solubility in DMSO
- Nab-Paclitaxel Storage
- Nab-Paclitaxel Stability
- Nab-Paclitaxel Molecular Weight
- Nab-Paclitaxel Chemical Structure (2D and 3D)
- Nab-Paclitaxel Cayman (29314)? Try a better option.
- Nab-Paclitaxel Tocris (0553)? Try a better option.
- Nab-Paclitaxel APExBIO (B6349)? Try a better option.
- Nab-Paclitaxel CST (4903)? Try a better option.
- Nab-Paclitaxel Abcam (ab16667)? Try a better option.
- Nab-Paclitaxel SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.